Not exactly .. safety was established in HIV trial
Post# of 148169
(Total Views: 787)
Posted On: 10/03/2020 4:47:14 AM
Not exactly .. safety was established in HIV trials, efficacy suggested in M/M... It's going to be behind REGN & perhaps LLY's P/MABs for obvious reasons, but it should be ahead of HGEN and That Sham Company.
My question is: what reference spike protein REGN's used; if it's from six months ago, what are the odds the strain Trump and associates have has mutated, and what would REGN's PAB's binding affinity be as a result?
Reinfections may be a function of adaptive immunity decreasing over time, but genetic sequencing has shown mutations from first and second infections. Viral protein-targeting P/MABs largely have the same issue as classic vaccines in that regard.
My question is: what reference spike protein REGN's used; if it's from six months ago, what are the odds the strain Trump and associates have has mutated, and what would REGN's PAB's binding affinity be as a result?
Reinfections may be a function of adaptive immunity decreasing over time, but genetic sequencing has shown mutations from first and second infections. Viral protein-targeting P/MABs largely have the same issue as classic vaccines in that regard.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼